CT-132 is the first FDA-authorized prescription digital therapeutic for episodic migraine prevention, designed to reduce monthly migraine days when used alongside standard treatment through a smartphone-based platform. Supported by clinical studies, CT-132 has shown a significant decrease in monthly migraine days, improved quality of life, and reduced migraine-related disability. It is intended to complement existing treatment regimens without contraindications and may support future clinical benefit claims aligned with the FDA's guidance on Prescription Drug Use-Related Software.

Source: Click Therapeutics